The article seems relevant but won't a D4 agonist just downregulate the D4 receptors in the end? If there's a -/- mutation which already decreases novelty seeking behaviour and causes cognition problems, then that would be bad. Also, A-412,997 is insanely expensive and in very low quantities as far as I can see.
The D4-receptor is an interesting case, because it appears as if it is unusually resistant to homeostatic changes, meaning that it is actually immensely hard to either up or down-regulate it. It's a very unusual trait within neurotransmitter -receptors, but it's not entirely unheard of - Melatonin-receptors actually appear to be fairly hardy as well (alltho' not to as dramatic an extent), and even tho' many get tolerance towards exogenous melatonin, it does not appear to be permanent at all, and can be easily reversed with Valproic Acid.
So no, D4-agonism won't downregulate the D4-receptors - the reasons why some receptors in the brain is less responsive to stimuli and tolerance is as of yet... unknown, though. I actually learned this here at Longecity, and it was quite surprising to learn this about MT and D4 -receptors, but this is the truth, this is the cutting edge - every receptor is not made from the same cloth, it would appear.
The idea of a -/- mutation is interesting however... but I believe that the research so far, in the dopamine-hypothesis of Schizophrenia, is that it is as a matter of fact the D2-receptors that are involved in the disorder, and not the D4 -receptors. It may be that D4 -agonism may actually be treating the negative symptoms in a round-about way, and not directly.
Since D4 handles cognition, it may simply be that it's simply because it's the one D-receptor not involved in the disorder, that agonising it won't trigger symptoms, and hence, you can reverse some of the problems that are caused by the Low-dopamine phases of the disorder.
"Schizophrenia: More dopamine, more D2 receptors"
http://www.ncbi.nlm....icles/PMC33999/
It should also be noted that the dopamine-hypothesis have strong competition from the Glutamate-hypothesis concerning Schizophrenia - and the unifying hypothesis, the Kynurenic Acid Hypothesis, is gaining ground and looks to actually be replacing both of them in the next decade or so - there are already several Kyna-based medications for Schizo being developed, if they work, then we know the two earlier ones were bull-sh*t. (a bit like the Serotonin-hypothesis in depression)
In closing, as far as I know, no extremely short variation of the DRD4 -gene have as of yet been identified to be connected to any disease, in fact, it seems to be the opposite. It should be noted, the D4-receptor is the least common D-receptor in the CNS, and it can only be found in the brain, the PFC to be accurate, which is again, a very atypical feature of a neurotransmitter receptor.
Edited by Stinkorninjor, 02 November 2015 - 01:13 AM.